Research programme: purinoceptor P2X3 antagonists - NEOMED

Drug Profile

Research programme: purinoceptor P2X3 antagonists - NEOMED

Alternative Names: NEO-5024; P2X3 receptor antagonists - NEOMED

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer NEOMED
  • Class Analgesics; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cough; Pain; Visceral pain
  • No development reported Interstitial cystitis

Most Recent Events

  • 27 Jun 2018 Pharmacodynamics data from a preclinical trial in cough released by BELLUS Health
  • 08 Nov 2017 BELLUS Health announces intention to submit CTA to Health Canada for Cough in the second quarter of 2018
  • 18 Sep 2017 Pharmacodynamic data from preclinical studies in Cough released by BELLUS Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top